SAI SREYAS PHARMACEUTICAL PRIVATE LIMITED

Overview

SAI SREYAS PHARMACEUTICAL PRIVATE LIMITED is an active pharmaceutical ingredient (API) supplier with 8 active FDA Type II Drug Master Files, covering ALECTINIB INTERMEDIATE- TERT-BUTYL 6-CYANO-2-(2-(4-ETHYL-3-IODOPHENYL) PROPAN-2-YL)-1H-INDOLE-3-CARBOXYLATE (TBC) IH (CAS NUMBER- 1256584-75-4); OLANZAPINE INTERMEDIATE- 4-AMINO-2-METHYL-10H-THIENE[2,3-B][1,5]BENZODIAZEPINE HYDROCHLORIDE (OLZ-3) IH (CAS NUMBER- 138564-60-0); RESMETIROM INTERMEDIATE – 3,6-DICHLORO-4-ISOPROPYLPYRIDAZINE (DIP IH) (CAS NO. 107228-51-3); RESMETIROM INTERMEDIATE- N-CYANOACETYL URETHANE (NCA) (CAS 6629-04-5)”.; RIVAROXABAN INTERMEDIATE – 4-{4-[(5S)-5-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL}MORPHOLIN-3-ONE HYDROCHLORIDE (RVB-3); RIVAROXABAN INTERMEDIATE (2-{[(2S)OXIRAN-2-YL]METHYL}-1H-ISOINDOLE-1,3(2H)-DIONE (RIVB)), CAS NO. [161596-47-0].

API / Drug Master Files

SAI SREYAS PHARMACEUTICAL PRIVATE LIMITED holds 8 active (8 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• OLANZAPINE INTERMEDIATE- 4-AMINO-2-METHYL-10H-THIENE[2,3-B][1,5]BENZODIAZEPINE HYDROCHLORIDE (OLZ-3) IH (CAS NUMBER- 138564-60-0)Active2026-01-24
• RIVAROXABAN INTERMEDIATE- (5-CHLOROTHIOPHENE-2-CARBOXYLIC ACID (RIV-C)), (CAS NO. 24065-33-6)Active2025-11-28
• RIVAROXABAN INTERMEDIATE (2-{[(2S)OXIRAN-2-YL]METHYL}-1H-ISOINDOLE-1,3(2H)-DIONE (RIVB)), CAS NO. [161596-47-0]Active2025-10-30
• RESMETIROM INTERMEDIATE – 3,6-DICHLORO-4-ISOPROPYLPYRIDAZINE (DIP IH) (CAS NO. 107228-51-3)Active2025-09-18
• RIVAROXABAN INTERMEDIATE – 4-{4-[(5S)-5-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL}MORPHOLIN-3-ONE HYDROCHLORIDE (RVB-3)Active2025-08-25
• ALECTINIB INTERMEDIATE- TERT-BUTYL 6-CYANO-2-(2-(4-ETHYL-3-IODOPHENYL) PROPAN-2-YL)-1H-INDOLE-3-CARBOXYLATE (TBC) IH (CAS NUMBER- 1256584-75-4)Active2025-08-06
• RESMETIROM INTERMEDIATE- N-CYANOACETYL URETHANE (NCA) (CAS 6629-04-5)”.Active2025-07-09
• SITAGLIPTIN INTERMEDIATE [3-(TRIFLUOROMETHYL)-5H,6H,7H,8H-[1,2,4] TRIAZOLO[4,3-A] PYRAZINE HYDROCHLORIDE)]Active2023-12-11

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to SAI SREYAS PHARMACEUTICAL PRIVATE LIMITED in our records. PharmaTek screens the full directory against live FDA enforcement data.